KEAP1 and cancer: Aberrant KEAP1-NRF2 signaling in NSCLC has both cancer cell-autonomous and non-autonomous effects, driving unique metabolic and immunological states, which suggests that combined targeting the metabolic vulnerabilities of cancer cells and disrupting their close interaction with the TIME would provide a more effective approach for this disease.